Leflunomid Aristo (Leflunomide)

Leflunomide inhibits the mitochondrial enzyme dihydroorotate dehydrogenase, blocking de novo pyrimidine synthesis. This limits the proliferation of activated T‑ and B‑lymphocytes, leading to reduced cytokine production and a dampened immune‑mediated inflammatory response that drives rheumatoid and psoriatic arthritis.

The dosage of Leflunomid Aristo is determined by the prescribing physician based on the patient’s clinical condition, weight, renal and hepatic function, and other individual factors. The prescriber will select the appropriate strength and dosing schedule in accordance with approved labeling and local guidelines.

Leflunomid Aristo is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of known teratogenic risk. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant. Effective contraception is required for women of child‑bearing potential.

To request Leflunomid Aristo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It may be used as monotherapy or in combination, but clinicians consider individual efficacy, safety profile, liver function impact and patient tolerance when selecting between agents.

Leflunomid Aristo should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Leflunomid Aristo is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should follow the exact dosing instructions provided, swallow the tablet whole with water, and attend regular follow‑up appointments for monitoring.

The most serious risks include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and teratogenic effects that can cause fetal malformations. Regular monitoring of liver enzymes, skin condition, and adherence to contraception are essential to mitigate these hazards.

Leflunomid Aristo is contraindicated in pregnant women, individuals with severe hepatic impairment, and patients with known hypersensitivity to leflunomide or its excipients. Caution is also advised for those with uncontrolled hypertension, active infections, or those receiving live vaccines.